# Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

> **NCT00055640** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate
- **GENETIC:** microarray analysis

## Key facts

- **NCT ID:** NCT00055640
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2005-04
- **Final completion:** 2006-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2010-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00055640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00055640, "Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00055640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*